3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Philadelphia Chromosome
2
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia
1
Interventions
Cyclophosphamide
7
fludarabine
6
Whole-Body Irradiation
6
Tacrolimus
6
Mycophenolic Acid
6
ruxolitinib
5
fludarabine phosphate
5
Melphalan
5
venetoclax
4
Peripheral Blood Stem Cell Transplantation
4
itacitinib
3
Specimen Handling
3
Sirolimus
3
Granulocyte Colony-Stimulating Factor
3
Cytarabine
3
Biopsy
3
Azacitidine
3
navitoclax
2
luspatercept
2
Etoposide
2
Daunorubicin
2
Busulfan
2
Antilymphocyte Serum
2
thymoglobulin
1
selinexor
1
quizartinib
1
pomalidomide
1
plerixafor
1
pevonedistat
1
parsaclisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Myeloproliferative Disorders
×
asciminib
×
Clear all
NCT05456191
2026-05-27
ASC4START
Novartis
Phase 3
Active not recruiting
568 enrolled
11 charts